Chiome Bioscience Inc
TSE:4583
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chiome Bioscience Inc
TSE:4583
|
JP |
|
Jupiter Wagons Ltd
NSE:JWL
|
IN |
Balance Sheet
Balance Sheet Decomposition
Chiome Bioscience Inc
Chiome Bioscience Inc
Balance Sheet
Chiome Bioscience Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
5 576
|
1 301
|
4 553
|
4 027
|
2 329
|
2 106
|
2 686
|
1 791
|
1 727
|
1 326
|
2 063
|
1 205
|
|
| Cash Equivalents |
5 576
|
1 301
|
4 553
|
4 027
|
2 329
|
2 106
|
2 686
|
1 791
|
1 727
|
1 326
|
2 063
|
1 205
|
|
| Short-Term Investments |
0
|
2 799
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
81
|
102
|
79
|
76
|
77
|
131
|
114
|
62
|
145
|
108
|
75
|
102
|
|
| Accounts Receivables |
37
|
46
|
47
|
44
|
42
|
95
|
57
|
25
|
115
|
83
|
51
|
72
|
|
| Other Receivables |
44
|
57
|
32
|
32
|
35
|
36
|
58
|
36
|
30
|
25
|
24
|
30
|
|
| Inventory |
55
|
42
|
35
|
35
|
45
|
67
|
89
|
59
|
71
|
64
|
46
|
49
|
|
| Other Current Assets |
26
|
29
|
14
|
59
|
159
|
258
|
359
|
305
|
149
|
131
|
153
|
191
|
|
| Total Current Assets |
5 737
|
4 274
|
4 682
|
4 197
|
2 610
|
2 561
|
3 249
|
2 217
|
2 092
|
1 629
|
2 338
|
1 547
|
|
| PP&E Net |
399
|
436
|
35
|
23
|
16
|
11
|
7
|
4
|
2
|
1
|
0
|
36
|
|
| PP&E Gross |
399
|
436
|
35
|
23
|
16
|
11
|
7
|
4
|
2
|
1
|
0
|
36
|
|
| Accumulated Depreciation |
397
|
484
|
589
|
430
|
433
|
409
|
384
|
383
|
349
|
318
|
313
|
294
|
|
| Intangible Assets |
25
|
23
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
114
|
0
|
150
|
150
|
150
|
150
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
73
|
73
|
72
|
50
|
55
|
86
|
89
|
118
|
121
|
121
|
131
|
144
|
|
| Other Assets |
24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6 257
N/A
|
4 919
-21%
|
4 789
-3%
|
4 419
-8%
|
2 831
-36%
|
2 808
-1%
|
3 495
+24%
|
2 339
-33%
|
2 215
-5%
|
1 751
-21%
|
2 469
+41%
|
1 728
-30%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
44
|
30
|
23
|
28
|
32
|
30
|
40
|
30
|
32
|
38
|
27
|
37
|
|
| Accrued Liabilities |
50
|
56
|
32
|
31
|
27
|
22
|
37
|
44
|
33
|
32
|
30
|
15
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
180
|
183
|
184
|
291
|
282
|
87
|
|
| Current Portion of Long-Term Debt |
0
|
46
|
50
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
201
|
105
|
64
|
98
|
54
|
93
|
86
|
135
|
122
|
178
|
155
|
236
|
|
| Total Current Liabilities |
295
|
238
|
169
|
161
|
113
|
145
|
343
|
393
|
370
|
539
|
493
|
375
|
|
| Long-Term Debt |
0
|
54
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
175
|
|
| Deferred Income Tax |
15
|
13
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
12
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
108
|
50
|
51
|
41
|
41
|
41
|
42
|
54
|
54
|
55
|
55
|
56
|
|
| Total Liabilities |
429
N/A
|
355
-17%
|
224
-37%
|
202
-10%
|
154
-23%
|
187
+21%
|
385
+106%
|
446
+16%
|
425
-5%
|
594
+40%
|
549
-8%
|
605
+10%
|
|
| Equity | |||||||||||||
| Common Stock |
4 435
|
4 445
|
5 186
|
5 455
|
5 455
|
6 132
|
1 388
|
1 516
|
2 097
|
2 388
|
996
|
1 086
|
|
| Retained Earnings |
3 031
|
4 316
|
5 797
|
6 682
|
8 223
|
9 633
|
1 265
|
2 738
|
4 003
|
5 219
|
1 011
|
1 989
|
|
| Additional Paid In Capital |
4 425
|
4 435
|
5 176
|
5 445
|
5 445
|
6 122
|
2 987
|
3 116
|
3 697
|
3 988
|
1 936
|
2 026
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
5 828
N/A
|
4 564
-22%
|
4 565
+0%
|
4 218
-8%
|
2 677
-37%
|
2 622
-2%
|
3 110
+19%
|
1 893
-39%
|
1 791
-5%
|
1 158
-35%
|
1 920
+66%
|
1 122
-42%
|
|
| Total Liabilities & Equity |
6 257
N/A
|
4 919
-21%
|
4 789
-3%
|
4 419
-8%
|
2 831
-36%
|
2 808
-1%
|
3 495
+24%
|
2 339
-33%
|
2 215
-5%
|
1 751
-21%
|
2 469
+41%
|
1 728
-30%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
22
|
22
|
25
|
27
|
27
|
33
|
40
|
41
|
48
|
53
|
67
|
68
|
|